After Rocket Pharmaceuticals (RCKT) announced that the FDA has lifted the hold on RPA501 for Danon following alignment on a modified dosage and a revised immunomodulatory regimen, Citi argues based on the news that the FDA may take “a more comprehensive look” at the level of immunomodulation required for Sarepta’s (SRPT) Elevidys and determine that additional steps beyond sirolimus are recommended or required for non-ambulatory patients. Citi has a Sell rating and $14 price target on Sarepta shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target raised to $17 from $10 at BofA
- Cautious Outlook on Sarepta Therapeutics Amid Uncertain Elevidys Launch and PMO Franchise Risks
- High-Risk Concerns Lead to Sell Rating for Sarepta Therapeutics Due to Elevidys Safety Profile
- Sarepta says Elevidys Citizen Petition misrepresents treatment-related deaths
- Hold Rating on Sarepta Therapeutics Amid Strategic Sale and siRNA Data Uncertainty